In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins.

A potential strategy introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within the cells.

Zydus Lifesciences shares were last seen 0.41 per cent up at Rs 891.55. At this price, the stock has slipped 8.43 per cent in ...

Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the United States ...

Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval from the United States Food ...

Researchers from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles, identified that ...

Zydus Lifesciences receives USFDA approval to manufacture generic Niacin extended-release tablets for lowering cholesterol.

Zydus Lifesciences Limited has earned USFDA approval for Niacin Extended-Release Tablets used to treat high cholesterol.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan ...